Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin Academic Article uri icon

  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All


  • Abstract Objective  Recent European Guidelines for Diabetes, Prediabetes and Cardiovascular Diseases introduced a shift in managing patients with type 2 diabetes at high risk for or established cardiovascular (CV) disease by recommending GLP-1 receptor agonists and SGLT-2 inhibitors as initial glucose-lowering therapy. This is questioned since outcome trials of these drug classes had metformin as background therapy. In this post hoc analysis, the effect of dulaglutide on CV events was investigated according to the baseline metformin therapy by means of a subgroup analysis of the Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial. Research design and methods  Patients in REWIND (n = 9901; women: 46.3%; mean age: 66.2 years) had type 2 diabetes and either a previous CV event (31%) or high CV risk (69%). They were randomized (1:1) to sc. dulaglutide (1.5 mg/weekly) or placebo in addition to standard of care. The primary outcome was the first of a composite of nonfatal myocardial infarction, nonfatal stroke, and death from cardiovascular or unknown causes. Key secondary outcomes included a microvascular composite endpoint, all-cause death, and heart failure. The effect of dulaglutide in patients with and without baseline metformin was evaluated by a Cox regression hazard model with baseline metformin, dulaglutide assignment, and their interaction as independent variables. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated by a Cox regression model with adjustments for factors differing at baseline between people with vs. without metformin, identified using the backward selection. Results  Compared to patients with metformin at baseline (n = 8037; 81%), those without metformin (n = 1864; 19%) were older and slightly less obese and had higher proportions of women, prior CV events, heart failure, and renal disease. The primary outcome occurred in 976 (12%) participants with baseline metformin and in 281 (15%) without. There was no significant difference in the effect of dulaglutide on the primary outcome in patients with vs. without metformin at baseline [HR 0.92 (CI 0.81–1.05) vs. 0.78 (CI 0.61–0.99); interaction P = 0.18]. Findings for key secondary outcomes were similar in patients with and without baseline metformin. Conclusion  This analysis suggests that the cardioprotective effect of dulaglutide is unaffected by the baseline use of metformin therapy.


  • Ferrannini, Giulia
  • Gerstein, Hertzel Chaim
  • Colhoun, Helen Martina
  • Dagenais, Gilles R
  • Diaz, Rafael
  • Dyal, Leanne
  • Lakshmanan, Mark
  • Mellbin, Linda
  • Probstfield, Jeffrey
  • Riddle, Matthew Casey
  • Shaw, Jonathan Edward
  • Avezum, Alvaro
  • Basile, Jan Neil
  • Cushman, William C
  • Jansky, Petr
  • Keltai, Mátyás
  • Lanas, Fernando
  • Leiter, Lawrence Alan
  • Lopez-Jaramillo, Patricio
  • Pais, Prem
  • Pīrāgs, Valdis
  • Pogosova, Nana
  • Raubenheimer, Peter Johann
  • Sheu, Wayne Huey-Herng
  • Rydén, Lars

publication date

  • July 8, 2021

has subject area